Association of Vaginal Estradiol Tablet With Serum Estrogen Levels in Women Who Are Postmenopausal: Secondary Analysis of a Randomized Clinical Trial

28/11/2022,
Serge Rozenberg

Dear colleagues and friends,

Here is Share Obgyn 926 mitchell_2022_oi_221179_1667492197.67542

Kind regards

Serge Rozenberg

Caroline M Mitchell et al compare serum estrogen concentrations with the use of vaginal

estrogen, 10 μg, tablet vs placebo in women who are postmenopausal. (JAMA Netw Open.

2022 Nov 1;5(11):e2241743. doi: 10.1001/jamanetworkopen.2022.41743.) in a secondary,

post hoc analysis of data from a randomized clinical trial of treatment for moderate to

severe genitourinary syndrome in women who are postmenopausal. In this post hoc

analysis, baseline and week 12 serum estradiol, estrone, and sex hormone-binding globulin

(SHBG) concentrations were measured by a chemiluminescent assay. A total of 174 women,

mean (SD) age 61 (4) years, were included. Those in the estrogen group (n = 88) were more

likely to have higher geometric mean (SD) week 12 serum estradiol concentrations (4.3 [2.2

pg/mL]) than those in the placebo group (n = 86) (3.5 [2.1] pg/mL) (P = .01). Adjusted for

pretreatment hormone concentrations, age, clinical site, and body mass index, assignment

to the estrogen vs placebo treatment group was significantly associated with higher week

12 estradiol concentrations (23.8% difference; 95% CI, 6.9%-43.3%). Most (121 of 174

[69.5%]) participants had enrollment serum estradiol concentrations higher than 2.7 pg/mL.

Of women starting treatment at estradiol levels lower than or equal to 2.7 pg/mL, 38.1% (8

of 21) in the estrogen group and 34.4% (11 of 32) in the placebo group had estradiol

concentrations higher than 2.7 pg/mL after 12 weeks of study participation (P = .78).

Treatment assignment was not associated with week 12 estrone or SHBG concentrations.

Conclusions and relevance: In this secondary analysis of a randomized clinical trial, a

significant, although small, increase in serum estradiol levels was noted after 12 weeks of

vaginal estrogen administration. The clinical relevance of this small increase is uncertain.

SHARING-OBGYN is a service that I intend to share with you. The idea is to send short email messages concerning an article that appeared recently and might be of interest to you. The selection of the articles is arbitrary, but there are no commercial interests involved and no conflict of interest.

If you want to be removed from the list of persons to whom these emails are sent please let me know.

If you want to bring comments or add email addresses of friends or colleagues, please feel free to do so.

Next meeting

11/03/2023
Cognitive disorders, depression and work ability at the menopause.

Latest news

06/01/2023
Menopausal hormone therapy reduces the risk of fracture regardless of falls risk or baseline FRAX probability-results from the Women's Health Initiative (WHI) hormone therapy trials